Leonard Zehr, Author at BioTuesdays

Markets

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...

May 13, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022

Developments

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani Therapeutics (NASDAQ:RANI) took top honors for its RaniPill capsule in the health category of Fast Company‘s 2022 World Changing Ideas. The RaniPill capsule is about the size of a standard fish oil pill...

May 3, 2022

Feature

Talking mental health with Chris Wang of Shimmer

As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first job with Bain & Co. But a close family...

May 3, 2022

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Markets

BTIG ups Biodesix PT to $17 from $10

BTIG raised its price target for Biodesix (NASDAQ:BDSX) to $17 from $10, saying “performance this year should restore investor confidence.” The stock closed at $1.61 on April 14. Analyst Sung Ji Nam writes that the...

April 15, 2022

Feature

In conversation with Dr. Murat Kalayoglu of Cartesian

As president and CEO of closely-held Cartesian Therapeutics, Murat Kalayoglu, M.D., Ph.D., has made a smooth transition over the years from a board-certified ophthalmologist to a healthcare IT entrepreneur to a medical...

April 12, 2022

Developments

Cannabotech partners with go NXT LVL to make oncology products in California

Closely-held Cannabotech of Israel entered a new strategic partnership with go NXT LVL of California to develop and manufacturing Cannabotech’s oncology products at go NXT LVL’s facilities in accordance with the...

April 6, 2022

Feature

Cocrystal Pharma advancing programs in high-value antiviral drug targets

With a drug discovery technology platform developed by several Nobel Prize laureates, Cocrystal Pharma (NASDAQ:COCP) is advancing broad spectrum antivirals in three programs: coronaviruses and variants, pandemic and...

April 5, 2022

Author - Leonard Zehr

HCW cuts Pulse Biosciences to neutral; withdraws PT

Qualigen advancing platform technologies in therapeutics and diagnostics

Analysts downgrade Amarin; PTs cut to $3

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Talking mental health with Chris Wang of Shimmer

Claritas Pharmaceuticals transforming nitric oxide therapy

BTIG ups Biodesix PT to $17 from $10

In conversation with Dr. Murat Kalayoglu of Cartesian

Cannabotech partners with go NXT LVL to make oncology products in California

Cocrystal Pharma advancing programs in high-value antiviral drug targets

Subscribe